Who is sponsoring NCT00072384?

NCT00072384 is sponsored by Children's Oncology Group.

What condition does NCT00072384 study?

NCT00072384 studies Intraocular Retinoblastoma.

What drugs are being tested in NCT00072384?

Interventions: liposomal vincristine sulfate, cryosurgery, laser surgery, carboplatin, etoposide, filgrastim.

What is the status of NCT00072384?

NCT00072384 is currently COMPLETED.

Last reviewed 2021-07-30 · How we verify

Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

NCT00072384 PHASE3 COMPLETED Results posted

Phase III trial to determine the effectiveness of combining systemic chemotherapy and subtenon carboplatin with ophthalmic therapy in treating children who have intraocular retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether systemic chemotherapy and subtenon (under the conjunctiva of the eye) carboplatin combined with ophthalmic therapy is effective in treating intraocular (within the eyeball) retinoblastoma.

Details

Lead sponsor	Children's Oncology Group
Phase	PHASE3
Status	COMPLETED
Enrolment	30
Start date	Mon Apr 16 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Intraocular Retinoblastoma

Interventions

liposomal vincristine sulfate
cryosurgery
laser surgery
carboplatin
etoposide
filgrastim

Countries

United States